全文获取类型
收费全文 | 3604篇 |
免费 | 198篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 183篇 |
妇产科学 | 42篇 |
基础医学 | 369篇 |
口腔科学 | 59篇 |
临床医学 | 368篇 |
内科学 | 919篇 |
皮肤病学 | 185篇 |
神经病学 | 173篇 |
特种医学 | 819篇 |
外科学 | 283篇 |
综合类 | 39篇 |
预防医学 | 119篇 |
眼科学 | 20篇 |
药学 | 113篇 |
中国医学 | 5篇 |
肿瘤学 | 123篇 |
出版年
2022年 | 13篇 |
2021年 | 30篇 |
2020年 | 26篇 |
2019年 | 34篇 |
2018年 | 53篇 |
2017年 | 45篇 |
2016年 | 60篇 |
2015年 | 86篇 |
2014年 | 89篇 |
2013年 | 138篇 |
2012年 | 126篇 |
2011年 | 134篇 |
2010年 | 141篇 |
2009年 | 117篇 |
2008年 | 139篇 |
2007年 | 125篇 |
2006年 | 140篇 |
2005年 | 116篇 |
2004年 | 111篇 |
2003年 | 98篇 |
2002年 | 93篇 |
2001年 | 86篇 |
2000年 | 114篇 |
1999年 | 89篇 |
1998年 | 157篇 |
1997年 | 143篇 |
1996年 | 144篇 |
1995年 | 99篇 |
1994年 | 91篇 |
1993年 | 91篇 |
1992年 | 59篇 |
1991年 | 61篇 |
1990年 | 37篇 |
1989年 | 79篇 |
1988年 | 79篇 |
1987年 | 76篇 |
1986年 | 70篇 |
1985年 | 64篇 |
1984年 | 35篇 |
1983年 | 38篇 |
1982年 | 44篇 |
1981年 | 25篇 |
1980年 | 40篇 |
1979年 | 25篇 |
1978年 | 17篇 |
1977年 | 18篇 |
1976年 | 25篇 |
1975年 | 31篇 |
1970年 | 7篇 |
1966年 | 9篇 |
排序方式: 共有3824条查询结果,搜索用时 15 毫秒
1.
Summary Experimental data suggest that multidrug resistance in cancer may be overcome by using an increased dose of anticancer agent(s) in combination with a resistance-modifying agent (RMA). We studied the pharmacokinetics and metabolism of both epirubicin (EPI) and verapamil (VPL) to explore the possible pharmacokinetic interactions between these two drugs. Ten patients with advanced breast cancer were given EPI (40 mg/m2 in a daily i.v. bolus for 3 consecutive days), and five of them also received VPL (4×120 mg/daily p.o. for 4 consecutive days). The data indicated a significant interaction between these two drugs that affected their metabolism. The areas under the concentration-time curves (AUC) obtained for epirubicin glucuronide, epirubicinol glucuronide, and both of the 7-deoxy-aglycones were higher in the EPI+VPL group as compared with the EPI group. The AUC, terminal half-life, mean residence time, volume of distribution at steady state, and plasma clearance of EPI alone as compared with EPI+VPL did not differ significantly. These results suggest either an induction of enzymes necessary for drug metabolism or an increase in the liver blood flow, resulting in an enhanced generation of metabolites with time or in an inhibition of excretion processes. Comparisons of the AUC values obtained for EPI and its metabolites after the first, second, and third injections of EPI revealed a cumulative effect for the metabolites that was more pronounced in the EPI+VPL group, being significant (P<0.05) for epirubicin glucuronide in both treatment groups and for epirubicinol glucuronide in the EPI+VPL group. Maximal concentrations of VPL and nor-VPL reached 705±473 and 308±122 ng/ml, respectively, with the steady-state concentrations being 265±42 ng/ml for VPL and 180±12 ng/ml for nor-VPL.This study was supported by the Erich und Gertrud Roggenbuck-Stiftung zur Förderung der Krebsforschung (Hamburg). The anthracycline metabolites were kindly provided by Dr. A. Suarato (Farmitalia, Milano, Italy); nor verapamil was provided by Dr. Traugott (Knoll, Ludwigshafen, Germany) 相似文献
2.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
3.
JA HYEON KU CHEOL KWAK SEUNG-JUNE OH EUNSIK LEE SANG EUN LEE JAE-SEUNG PAICK 《International journal of urology》2004,11(7):489-493
BACKGROUND: Our aims in the present study were to estimate the influences of pain and urinary symptoms on quality of life, and to determine which of these two variables has the most predictive power with respect to quality of life in young men with chronic prostatitis-like symptoms. METHODS: Chronic prostatitis-like symptoms were measured by the National Institutes of Health-Chronic Prostatitis Symptom Index. Of the 28,841 men aged 20 years who lived in the study community, 18,495 men (a response rate 64.1%) agreed to participate in the study. A total of 1057 men who complained of symptoms indicative of chronic prostatitis were included in the study. The influences of pain and urinary symptoms on quality of life were determined using logistic regression analysis. The receiver operating characteristic (ROC) curve was used to estimate the predictive ability of each of these variables with respect to quality of life. RESULTS: Results from multivariate analysis showed that both pain and urinary symptoms were associated with an increased likelihood of impaired quality of life, although pain contributed more to a reduced quality of life than urinary symptoms. Relative to men who experienced mild pain, men who experienced moderate pain had a 3.9-fold risk of poor quality of life (odds ratio [OR], 3.87; 95% confidence interval [CI], 2.86-5.23; P < 0.001) and those who experienced severe pain had a 15.7-fold risk of reduced quality of life (OR, 15.68; 95% CI, 6.59-37.35; P < 0.001). Moderate urinary symptoms were associated with a 1.4-fold risk of bother (OR, 1.41; 95% CI, 1.01-1.99; P < 0.001) and severe urinary symptoms were associated with 2.4-fold risk (OR, 2.39; 95% CI, 1.37-4.12; P < 0.001), relative to mild urinary symptoms. Comparison of the effects of pain and urinary symptoms showed that pain severity had the most predictive power for bother, quality of life, and quality-of-life impact. The areas under the ROC curves for bother, quality of life, and quality-of-life impact were 71.3%, 69.3% and 72.5%, respectively. CONCLUSION: Urinary symptoms and pain might be associated with an increased likelihood of impaired quality of life in young men with chronic prostatitis-like symptoms. In addition, our findings suggest that pain severity is the most influential variable for determining quality of life in this population. 相似文献
4.
Sabrina Benedetto Roberta Pulito Simonetta Geninatti Crich Guido Tarone Silvio Aime Lorenzo Silengo Jrg Hamm 《Magnetic resonance in medicine》2006,56(4):711-716
Targeted imaging requires site-specific accumulation of a contrast agent (CA), and the properties of that agent must be selected according to the abundance of the target to obtain a signal above the detection limit of the instrument. However, numerical estimates of receptors per cell are rarely found in the literature. Integrin receptors would be particularly promising targets because of their accessibility from the blood stream and expression on activated neovascular endothelial cells. We systematically estimated the number of integrin receptors of cell lines and primary cells by flow cytometry analysis. Since integrin receptors are heterodimeric molecules, and alpha(v) forms complexes with various beta subunits, the numbers of alpha(v) and beta(3) subunits are therefore dissimilar. The observed values are 3 . 10(3)-1.4 . 10(4)/cell for alpha(v), and 5.3 . 10(2)-1.1 . 10(4)/cell for beta(3). Despite the low number of exposed receptors, we show that up to single-cell MR visualization can be achieved with the use of iron oxide beads complexed with antibodies as CAs. 相似文献
5.
6.
7.
MRI is estabished as a modality available for use in the diagnosis of cervical cancer. The soft tissue contrast it supplies is far better than that of any other method, making it the modality of choice for direct visualization of the carcinoma and thus also for tumor staging. Pelvic MRI performed as part of the pretreatment evaluation has been shown to be cost effective, and it is recommended for use in macroscopic cervical cancer in the guidelines of professional societies for gynecologists and oncologists. It has proved to be a reliable method for the early detection of recurrent tumors. It remains unsurpassed for accurate visualization of local tumor extent and involvement of adjacent pelvic organs in recurrent cervical cancer. It is also the method of choice for use in the planning of brachytherapy. With the increasing use of PET and PET/CT for investigations in oncology patients a second method has emerged. This seems to have advantages particularly in the detection of lymph node metastases by whole-body examination. Encouraging results on detection of recurrent cervical cancer during follow-up treatment by PET/CT have also been published, but a definitive assessment of the value of PET in tumor aftertreatment cannot be reached without more comparative studies against MRI. Moreover, there have so far been no studies evaluating the cost effectiveness of PET. In the near future it will be necessary to reconsider the new diagnostic modalities with reference to their accuracy in staging, since therapy is oriented increasingly to disease stage and increasingly specific treatment methods are applied. 相似文献
8.
9.
10.